Core Viewpoint - Jiet Bio announced the appointment of Mr. Bao Minzhang as the secretary of the board of directors, effective from the date of the board meeting held on January 19, 2026, until the current board's term ends [2]. Group 1 - The fourth meeting of the fourth board of directors was held on January 19, 2026 [2]. - The board approved the proposal to appoint Mr. Bao Minzhang as the secretary of the board [2].

国联民生证券承销保荐有限公司 关于广州洁特生物过滤股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"或"保荐 机构"）作为广州洁特生物过滤股份有限公司（以下简称"洁特生物"或"公司"） 2022 年向不特定对象发行可转债并在科创板上市的保荐机构，根据《证券发行 上市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等有关规定，就洁特生物使用部分闲置募集资金暂时补充流动资金的事项 进行了核查，核查情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，公司向不特定对象共计发行 440.00 万张可转债，每张面值为人民币 100 元， 按面值发行。本次发行的募集资金总额为 440,000,000.00 元，扣除承销及保荐费、 律师费、验资费、资信评级费和发行手续费等与发行可转换公司债券直接相关的 外部费用后，实际募 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-006 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 重要内容提示： 广州洁特生物过滤股份有限公司关于 使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 暂时补流募集资金金额：20,000 万元 补流期限：自 2026 年 1 月 19 日第四届董事会第二十七次会议审议通 过起不超过 12 个月 一、募集资金基本情况 | 发行名称 | 2022 | | | | 年向不特定对象发行可转换公司债券 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 募集资金总额 | | | | 44,000.00 | | 万元 | | | 募集资金净额 | | | | 43,249.15 | | 万元 | | | 募集资金到账时间 | | | 2022 | | 年 7 月 | 4 日 | | | 前次用于暂时补 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-005 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于 2026 年 1 月 19 日 召开了第四届董事会第二十七次会议，审议通过了《关于公司聘任董事会秘书的 议案》。为保证董事会的日常运作及公司信息披露等工作的开展，根据《公司法》 和《公司章程》的相关规定，经公司董事长提名并经董事会提名委员会资格审查， 董事会同意聘任鲍珉璋先生（简历详见附件）为公司董事会秘书，任期自本次董 事会审议通过之日起至本届董事会任期届满止。 鲍珉璋先生已取得上海证券交易所科创板董事会秘书任职培训证明，具备 履行董事会秘书职责所需的工作经验和专业知识，具有良好的职业道德和个人品 质，不存在相关法律法规规定的禁止任职的情况，符合《公司法》《上海证券交 易所科创板股票上市 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-004 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十 七次会议于 2026 年 1 月 19 日（星期一）以通讯的方式召开。会议通知已于 2026 年 1 月 14 日通过邮件的方式送达各位董事。本次会议应出席董事 7 人，实际出 席董事 7 人。 会议由董事长袁建华主持，部分高级管理人员列席了本次会议。会议召开 符合有关法律、法规、规章和《公司章程》的规定。经各位董事认真审议，会议 形成了如下决议： 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《关于 使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2026-006）。 表决结果：7 票同意，0 票反对，0 票弃权。 特此公告。 ...

Group 1 - The core point of the news is that Jiet Bio has seen a continuous increase in its stock price, rising 1.27% to 17.60 CNY per share, with a total market capitalization of 2.47 billion CNY and a cumulative increase of 5.39% over the past six days [1] - Jiet Bio specializes in the research, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling, with revenue composition being 60.24% from liquid handling, 30.74% from biological culture, and 4.98% from other sources [1] - The company is located in the Guangzhou Economic and Technological Development Zone and was established on April 11, 2001, with its listing date on January 22, 2020 [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in Jiet Bio, with its fund holding 120,600 shares, representing 1.36% of the fund's net value, making it the sixth-largest holding [2] - The Huashang SSE STAR Market Comprehensive Index Enhanced A fund has a current scale of 87.04 million CNY and has achieved a year-to-date return of 7.58%, ranking 1517 out of 5520 in its category [2] - The fund managers, Ai Dingfei and Hai Yang, have notable performance records, with Ai having a best return of 144.96% during his tenure and Hai achieving a best return of 65.86% [2]

Core Viewpoint - The actual controller of Guangzhou Jiete Biological Filtration Co., Ltd., Yuan Jianhua, reduced his holdings in the company's convertible bonds, leading to a decrease in his combined equity stake in the company. Group 1: Equity Change Details - On January 7, 2026, Yuan Jianhua reduced his holdings by 200,000 convertible bonds, which represents 4.55% of the total convertible bonds issued, totaling 4,399,430 [2][4] - This reduction caused his combined equity stake to decrease from 29.26% to 27.86%, a change of 1.40% [2][4] - The combined equity stake of the actual controller and his concerted parties decreased from 44.37% to 42.05%, a change of 2.32% due to this transaction [2][4] Group 2: Pre and Post-Change Equity Situation - Before the change, Yuan Jianhua and his concerted parties held a combined equity stake of 29.26% and 44.37%, respectively, calculated based on the higher of their direct shareholding or the convertible bonds [5] - After the change, their combined equity stakes are now 27.86% and 42.05%, respectively [6] Group 3: Transaction Nature - The equity change was a result of a bulk transaction of convertible bonds and did not trigger a mandatory tender offer, meaning there will be no change in the actual control of the company [4][7]

Core Viewpoint - The actual controller of Guangzhou Jiete Biological Filtration Co., Ltd., Yuan Jianhua, reduced his holdings in the company's convertible bonds, leading to a decrease in his overall equity stake in the company. Summary by Sections 1. Equity Change Overview - On January 7, 2026, Yuan Jianhua reduced his holdings by 200,000 convertible bonds, which represents 4.55% of the total convertible bonds issued (4,399,430 bonds) [1][2] - This reduction caused his combined equity stake in the company to decrease from 29.26% to 27.86%, a change of 1.40% [1][2] - The combined equity stake of the actual controller and his concerted parties fell from 44.37% to 42.05%, a change of 2.32% [1][2] 2. Pre- and Post-Equity Change Situation - Before the equity change, Yuan Jianhua and his concerted parties held a combined equity stake of 29.26% and 44.37%, respectively, based on the higher of the two calculations [3] - After the equity change, their combined equity stakes are now 27.86% and 42.05%, respectively [4] 3. Subsequent Matters - The equity change was executed through a block trade of convertible bonds and did not trigger a mandatory tender offer, ensuring that there will be no change in the actual control of the company [2][4]

因上述人员减持公司可转债，导致公司实际控制人及其一致行动人拥有 公司的合并权益比例由 44.37%下降至 42.05%，变动 2.32%。 公司实际控制人及其一致行动人实际拥有的公司股份未发生变化。 本次权益变动系可转债大宗交易减持，不触及要约收购。 公司收到实际控制人袁建华先生的通知，2026 年 1 月 7 日袁建华通过大宗 交易方式合计减持公司可转债 200,000 张，占公司可转债总量 4,399,430 张的比 例为 4.55%；因本次减持公司可转债，导致其拥有公司的合并权益比例由 29.26% 下降至 27.86%，变动 1.40%。因上述人员减持公司可转债，导致公司实际控制 人及其一致行动人拥有公司的合并权益比例由 44.37%下降至 42.05%，变动 2.32%。现将有关权益变动情况公告如下： | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-003 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司关于 实际控制人之一减持可转换公司债券暨 权益变动的提示性公告 本公司董事会及全体董事 ...

■ 特此公告。 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于2025年12月29日召开第四届董事会第二十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份的议案》，具体情况详见公司于2025年12月31 日披露于上海证券交易所网站（www.sse.com.cn）的《关于以集中竞价交易方式回购股份方案的公告暨 回购报告书》（公告编号：2025-072）。根据《上海证券交易所上市公司自律监管指引第7号一一回购 股份》等相关规定，现将公司披露第四届董事会第二十六次会议公告回购股份决议的前一个交易日（即 2025年12月30日）登记在册的前10大股东和前10大无限售条件股东的名称及持股数量、比例情况公告如 下： 一、公司前十大股东持股情况 ■ 二、公司前十大无限售条件股东持股情况 广州洁特生物过滤股份有限公司董事会 2026年1月8日 ...